Long-term fetal outcome following chemotherapy exposure
| . | Follow up . | Outcome . | |
|---|---|---|---|
| Development . | Incidence of cancer . | ||
| Hematologic malignancy, N = 84; (AL, n = 29)26 | Age: 6-29 y (median, 18.7 y) | No congenital, neurological, or psychological abnormalities | No increased risk |
| First-trimester exposure, n = 38 | Normal reproductive development in 12 second-generation children | ||
| In utero exposure to chemotherapeutic agents, N = 111; (AL, n = 17)27 | Assessed age: 4-22 y | Normal neurodevelopment | — |
| Exposure to anthracyclines in utero, N = 81; (AL, n = 29)16 | Age: 9.3-29.5 y (mean 17.1 y) | No cardiac toxicity | — |
| Exposure to chemotherapy in utero post first trimester,95 N = 157 | Mean neonatal follow up: 3 y postpartum | No increase in congenital anomalies, preterm delivery, or growth restriction | — |
| N = 7096 | Median follow-up period of 22.3 mo (range, 16.8-211.6 mo) | No association with increased neurologic, cardiac, or auditory morbidity; no difference in overall health and growth compared with the general population | — |
| . | Follow up . | Outcome . | |
|---|---|---|---|
| Development . | Incidence of cancer . | ||
| Hematologic malignancy, N = 84; (AL, n = 29)26 | Age: 6-29 y (median, 18.7 y) | No congenital, neurological, or psychological abnormalities | No increased risk |
| First-trimester exposure, n = 38 | Normal reproductive development in 12 second-generation children | ||
| In utero exposure to chemotherapeutic agents, N = 111; (AL, n = 17)27 | Assessed age: 4-22 y | Normal neurodevelopment | — |
| Exposure to anthracyclines in utero, N = 81; (AL, n = 29)16 | Age: 9.3-29.5 y (mean 17.1 y) | No cardiac toxicity | — |
| Exposure to chemotherapy in utero post first trimester,95 N = 157 | Mean neonatal follow up: 3 y postpartum | No increase in congenital anomalies, preterm delivery, or growth restriction | — |
| N = 7096 | Median follow-up period of 22.3 mo (range, 16.8-211.6 mo) | No association with increased neurologic, cardiac, or auditory morbidity; no difference in overall health and growth compared with the general population | — |
AL, acute leukemia. Other abbreviations are explained in Table 1.